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Abstract
Neural stem/progenitor cells (NSPCs) have great potential as a cell replacement therapy for spinal cord injury. However,
poor control over transplant cell differentiation and survival remain major obstacles. In this study, we asked whether
dibutyryl cyclic-AMP (dbcAMP), which was shown to induce up to 85% in vitro differentiation of NSPCs into neurons would
enhance survival of transplanted NSPCs through prolonged exposure either in vitro or in vivo through the controlled release
of dbcAMP encapsulated within poly(lactic-co-glycolic acid) (PLGA) microspheres and embedded within chitosan guidance
channels. NSPCs, seeded in fibrin scaffolds within the channels, differentiated in vitro to betaIII-tubulin positive neurons by
immunostaining and mRNA expression, in response to dbcAMP released from PLGA microspheres. After transplantation in
spinal cord injured rats, the survival and differentiation of NSPCs was evaluated. Untreated NSPCs, NSPCs transplanted with
dbcAMP-releasing microspheres, and NSPCs pre-differentiated with dbcAMP for 4 days in vitro were transplanted after rat
spinal cord transection and assessed 2 and 6 weeks later. Interestingly, NSPC survival was highest in the dbcAMP pre-treated
group, having approximately 80% survival at both time points, which is remarkable given that stem cell transplantation
often results in less than 1% survival at similar times. Importantly, dbcAMP pre-treatment also resulted in the greatest
number of in vivo NSPCs differentiated into neurons (3764%), followed by dbcAMP-microsphere treated NSPCs (27614%)
and untreated NSPCs (1567%). The reverse trend was observed for NSPC-derived oligodendrocytes and astrocytes, with
these populations being highest in untreated NSPCs. This combination strategy of stem cell-loaded chitosan channels
implanted in a fully transected spinal cord resulted in extensive axonal regeneration into the injury site, with improved
functional recovery after 6 weeks in animals implanted with pre-differentiated stem cells in chitosan channels.
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Introduction
Repair after traumatic spinal cord injury (SCI) remains a
significant challenge. Extensive cell death and tissue disorganiza-
tion, including demyelination, coupled with an inherent aborted
and lack of spontaneous regeneration results in permanent
disruption of signalling pathways. Although resident endogenous
neuralstemcellsexistliningthe centralcanaloftheadultspinalcord
[1], their recruitment is limited in response to injury [2]. This is in
largepartduetotheinhibitoryenvironmentofadultcentralnervous
system (CNS) tissue, which is further exacerbated after injury.
Cell transplantation therapy is a promising approach to replace
the damaged or lost cells after SCI. In particular, adult neural stem/
progenitor cells (NSPCs) are attractive because of their ability to
form the three major CNS cell types exclusively. However, in
practice, NSPCs transplanted into the spinal cord have a much
greater tendency to differentiate into either astrocytes or oligoden-
drocytes, and rarely undergo neuronal differentiation in vivo
[3,4,5]. Indeed, many attempts to program NSPCs to preferentially
promote neuronal differentiation in vitro have notsucceededin vivoin
the spinal cord [6,7,8]. It is important to investigate the potential of
neuronal replacement strategies for SCI as neurons are the core
functional component of spinal cord signalling. Neuronal replace-
ment after SCI is important to areas rich in neurons such as the
cervical or thoraco-lumbar segments of the spinal cord.
The advantages of transplanting NSPCs in combination with
implants of biomaterial guidance channels have been described
[9,10,11]. After complete spinal cord transection injury in the rat,
new tissue formed between the two spinal cord stumps as early as five
weeks post injury [10]. Transplanted NSPCs were found to survive
and integrate into this tissue bridge, and were distributed throughout
thelengthofthebridge.However,veryfewNSPCsdifferentiatedinto
neurons and limited functional recovery occurred.
Directed differentiation of NSPCs can be accomplished through
exposure to specific soluble factors. For example, platelet-derived
growth factor has been shown to promote oligodendrocyte fate-
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astrocyte differentiation [13]. Zahir et al., screened several factors
for promoting neurogenesis from adult rat subventricular zone
(SVZ)-derived NSPCs and reported that dibutyryl cyclic-AMP
(dbcAMP), a membrane-permeable analogue of cyclic-AMP, and
the cytokine interferon-gamma both enhanced neuronal differen-
tiation after one week exposure in culture [14]. Several other
groups have used dbcAMP to differentiate a variety of neural stem
or progenitor cells into neurons [15,16,17,18]. This is thought to
be primarily through the PKA pathway [15], which causes
upregulation of cAMP-responsive element binding (CREB), an
important transcription factor in regulating neuronal activity [19].
Moreover, dbcAMP may have beneficial effects independent of its
action on NSPCs, particularly with respect to promoting axonal
regeneration [20]. It is a downstream molecule in neurotrophin
signaling [21,22], which has been shown to allow neurite
outgrowth in the presence of myelin inhibitors in vitro [21] and
in vivo [23].
In the present study, directed neuronal differentiation of NSPCs
with dbcAMP was characterized first in vitro on 2D chitosan film
surfaces and 3D fibrin scaffolds, and then in vivo in a rat spinal cord
transection model. Specifically, NSPCs were transplanted in
chitosan guidance channels in which the walls were loaded with
dbcAMP-eluting poly(lactic-co-glycolic acid) (PLGA) microspheres
[24]. We have recently shown that chitosan channels exhibit
excellent biocompatibility in the spinal cord over a one year period
[25]. Microsphere-based release of dbcAMP facilitates local and
sustained drug release, providing a potential method for in situ
differentiation. The effect of directed neuronal differentiation of
NSPCs with dbcAMP was evaluated for its effect on survival,
differentiation, and integration into the rat spinal cord following
SCI. As well, the timing of differentiation was also investigated:
NSPCs were either pre-differentiated in vitro prior to transplanta-
tion, or transplanted with dbcAMP-releasing microspheres for in
vivo differentiation. Finally, fibrin was used as a 3D scaffold to
entrap/suspend the cells within the channels. Fibrin hydrogel has
previously shown to be useful for stem cell transplantation to the
spinal cord [26].
Materials and Methods
Chitosan Films and Channels
High quality chitosan (Protosan UP B 80/20; NovaMatrix) was
dissolved as a 3 wt% solution in 2% acetic acid, and then diluted
with an equal volume of ethanol. Chitosan films were prepared by
allowing 10 ml of chitosan solution to air dry in a 10 cm Petri dish.
Once dry, the film was soaked in neutralization solution (90%
methanol, 7% water, 3% ammonium hydroxide) for 15 min then
washed thoroughly with water. Films were cut into 8 mm discs
and disinfected in 70% ethanol prior to use in cell culture studies.
Chitosan channels were prepared as previously described [27].
Briefly, chitosan/ethanol solution was reacted with acetic
anhydride and injected between concentric cylindrical glass molds,
resulting in chitin hydrogel channels with an inner diameter of
4 mm and outer diameter of 8 mm. Chitin channels were washed
for 24 h then were hydrolyzed in 40 wt% NaOH at 110uC for 2 h,
rinsed, then hydrolyzed again for another 25 min resulting in
chitosan with a degree of deacetylation of 85% as assessed by
1H-
NMR [28]. Upon washing, channels were air-dried on 3.7 mm
stainless steel rods. Channels were cut into 8 mm lengths.
PLGA microspheres were embedded along the inner walls of
chitosan channels as previously described [24]. Briefly, 5 mg of
blank or dbcAMP-containing PLGA microspheres (described
later), was suspended in 25 ml of a buffered chitosan solution
(1:5, v/v mixture of 2% chitosan in 1% acetic acid and 75 mM
phosphate buffer, pH 7). The microsphere solution was intro-
duced to the interior of channels under a rotation of 2500 rpm and
spun until dry. The microsphere-embedded channels were then
neutralized in a solution of 90% methanol, 7% water, and 3%
ammonium hydroxide for 1 min, rinsed thoroughly, and air dried.
Channels were then sterilized by gamma irradiation at a dose of
2.5 MRad prior to use in subsequent in vitro or in vivo cell culture
studies.
Dibutyryl Cyclic-AMP PLGA Microspheres
Poly(lactic-co-glycolic acid) (PLGA) 50/50 of both 0.20 and
0.37 g/dl inherent viscosity in hexafluoroisopropanol (HFIP) were
used as received from Lactel. PLGA microspheres were fabricated
using a W/O/W double emulsion procedure. The inner aqueous
phase consisted of 75 ml of ddH20 with or without 40 mg dibutyryl
cyclic-adenosine monophosphate (Sigma-Aldrich). 130 mg of
PLGA (80 wt% 0.20 g/dl, 20 wt% 0.37 g/dl) was dissolved in
600 ml of dichloromethane/acetone (3:1). The two solutions were
emulsified under sonication (Vibracell VCX 130, Sonics and
Materials) for 45 s using a 3 mm probe at 30% amplitude. This
emulsion was added to 25 ml of 2.5% polyvinyl alcohol (PVA)/
10% NaCl solution and homogenized at 4000 rpm for 60 s. The
resultant solution was poured into a 250 ml bath of 0.25% PVA/
10% NaCl solution under magnetic stirring. In a typical batch,
three identical preparations were added to the final bath. Four
hours later, the hardened microspheres were collected and washed
by centrifugation, then washed again over a 0.2 mm filter,
collected, lyophilized and stored at 220uC until use.
The amount of encapsulated dbcAMP was measured by
dissolving a known quantity of microspheres in 800 mlo f
dichloromethane. An equal volume of water was added and the
solution was vortexed and centrifuged for 3 min at 10 000 rpm.
The water phase containing drug was collected. This process was
repeated two more times. The collected water phase was then
measured for dbcAMP content using a Nanodrop UV spectrom-
eter at 273 nm against a calibration curve of known dbcAMP
solution concentrations. Encapsulation efficiency (EE) was calcu-
lated as the percentage of actual loading compared to the
maximum theoretical loading based on preparation parameters.
To measure the release of dbcAMP from microspheres or
microsphere-loaded channels, approximately 3 mg of micro-
spheres (accurately measured) or a single microsphere-loaded
channel was suspended in 1.8 ml PBS and stored under gentle
agitation at 37uC. At various times, 2 ml of the release buffer was
sampled for measurement by Nanodrop UV spectroscopy at
273 nm. Known concentrations of dbcAMP were incubated
alongside release samples, and a small but measurable decrease
in dbcAMP signal due to hydrolysis was observed over time and
was accounted for in drug release calculations. At the end of the
release period, mass balance measurement of the remaining
dbcAMP in microspheres was quantified by phase extraction in
dichloromethane.
Adult Neural Stem/Progenitor Cells
Primary NSPCs were isolated from the subventricular zone of
adult Wistar rats, both GFP and non-GFP, and propagated as
previously described [14]. The transgenic rats expressing GFP
(Wistar-TgN(CAG-GFP)184ys) were the gift of Dr. Armand
Keating (University of Toronto, Toronto) and have been
previously described [29,30]. NSPCs were passaged as neuro-
spheres in growth media: Neurobasal media (Gibco-Invitrogen),
B27 neural supplement (Gibco-Invitrogen), 2 mM L-glutamine
(Sigma-Aldrich), 100 mg/ml penicillin-streptomycin (Sigma-Al-
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fibroblast growth factor (Sigma-Aldrich), and 2 mg/ml heparin
(Sigma-Aldrich). NSPCs were used after the fourth or fifth passage
for in vitro and in vivo studies.
Chitosan Film Studies
Chitosan films were placed in 48-well plates and soaked in
media prior to use. NSPCs were spun down at 1500 rpm for 5 min
and the resultant pellet was re-suspended and dissociated in fresh
growth media, with or without dbcAMP. The cell solution was
then added so that each well contained 30 000 cells, and the final
volume of media in the wells was 500 ml. After 24 h, the media
was removed and replaced with differentiation media - Neurobasal
media containing B27 supplement, L-glutamine, penicillin-strep-
tomycin, and 1% FBS - with or without dbcAMP. Half-volume
media changes were performed every 48 h thereafter.
Chitosan Channel Studies
For cell culture studies in channels, NSPCs were seeded in
three-dimensional fibrin scaffolds. Fibrinogen (F3879; Sigma) was
dissolved as a 22.2 mg/ml solution in 0.03 M Tris buffered saline
(TBS), pH 7, filtered through a 0.22 mm filter, and then stored at
280uC. Thrombin (T6884; Sigma) and aprotinin (A4529; Sigma)
were similarly dissolved in TBS at concentrations of 24 NIHU/ml
and 5 mg/ml respectively, filtered and stored at 280uC.
On the day of use, fibrinogen, aprotinin, and laminin (Sigma)
solutions were combined, resulting in a solution of 20 mg/ml
fibrinogen, 500 mg/ml aprotinin, and 20 mg/ml laminin. This
solution was mixed 5:3 with media containing dissociated NSPCs.
The cell-fibrinogen mixture (48 ml) was then added by pipette into
the lumen of pre-hydrated chitosan channels, followed by 12 mlo f
thrombin solution. After mixing, the fibrin scaffold containing
NSPCs formed within thirty seconds. The initial cell number in
each fibrin-filled channel was 250 000.
Cell-seeded channels were then placed in 24-well plates
containing 1 ml of fresh growth media, with or without 1 mM
dbcAMP. For in vitro studies, the media was removed after 24 h
and replaced with differentiation media, with or without 1 mM
dbcAMP. Half-volume media changes were performed every 48 h
thereafter.
NSPC-seeded channels for in vivo studies were prepared
similarly using GFP-positive cells. Channels were implanted after
either 1 or 4 days in vitro (1div and 4div respectively), depending
on dbcAMP treatment (Table 1). The 1div channels did not
receive a media exchange prior to transplantation. The 4div
channels received media changes as described above, but FBS was
removed from the differentiation media. Excess samples from each
treatment group were prepared and fixed on the day of transplant
and analyzed for cell number and percentage of betaIII-positive
neurons.
Immunocytochemistry
For cell culture experiments, fixed samples were permeabilized
with PBS containing 0.3% Triton X-100 and 1% bovine serum
albumin (BSA) for 15 min followed by 1 h blocking in 1% BSA.
Samples were incubated for 2 h with primary antibodies including
mouse anti-betaIII tubulin (1:1000, Covance) for neurons, mouse
anti-GFAP (1:200, Millipore) for astrocytes, mouse anti-RIP (1:5,
DSHB) for oligodendrocytes, mouse anti-nestin (1:100, BD
Biosciences) for neural precursors, and mouse anti-Ki67 (1:100,
Novocastra Laboratories Ltd) for proliferating cells. Following
three 10 min washes in PBS, samples were incubated with goat
anti-mouse IgG Cy3 (1:500, Jackson Immunoresearch) for 1 h.
After another series of washes, samples were incubated with
10 mM Hoecsht 33342 (Invitrogen) nuclear dye and coverslipped
with Vectashield mounting media. A minimum of five randomly
selected fields per sample were photographed on an Olympus
BX61 epifluorescent microscope to quantify cells co-labelled with
nuclear dye and secondary antibody.
Quantitative RT-PCR
Cell culture samples were lysed after seven days and RNA was
collected and purified using RNAqueous Micro kit (Ambion).
Following RNA isolation and DNAse I treatment, total RNA
concentration and purity was measured using Nanodrop ND-
1000. RNA concentration was normalized across samples then
built into cDNA libraries using a AffinityScript RT kit (Strata-
gene).
Quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR) amplification was performed on a Light Cycler 480
(Roche) using SYBR Green II master mix kit (Roche). Following a
5 min activation at 95uC, fluorescent measurements were taken
after temperature cycles of 10 s at 90uC, 15 s at 65uC, and 10 sec
at 72uC. After 50 cycles, the temperature was held at 65uC for
1 min, followed by temperature ramping to 95uC over 8 min to
generate a melt curve. All qRT-PCR samples were performed in
triplicate. Gene expression for each sample was normalized to the
housekeeping gene HPRT. Primer design for target genes of
interest are previously reported [31]. Data is expressed as fold-
difference compared to undifferentiated (day 0) cells.
Animal Studies
The animal work was approved by the Animal Care Committee
of the University Health Network (Protocol No. AUP 125.15).
Adult female Sprague-Dawley rats (250–350 g, Charles River, St.
Constant, QC) were anesthesized with 4% isofluorane and an
oxygen/nitrous oxide (2:1) mixture. The isofluorane concentration
was dropped to 2% during the operation. Following incision of the
skin on the back, vertebral levels T6 to T10 were exposed.
Laminectomy was performed on T7 to T9 exposing the spinal
cord. The facets of the vertebrae at T7 to T9 were also removed. A
Table 1. In vivo treatment groups.
Group
Culture period
prior to
transplant (days)
1 mM dbcAMP
in media during
culture period?
Microsphere
Content
Cell Number
on Day of
Transplant (610
3)
Animals for
two-week
survival (n)
Animals for
six-week
survival (n)
Untreated, 1div 1 No No drug 83645 5
Untreated, 4div 4 No No drug 46683 -
dbcAMP-MS, 1div 1 No dbcAMP 78612 4 5
dbcAMP, 4div 4 Yes No drug 57610 4 6
doi:10.1371/journal.pone.0021744.t001
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the rostral and caudal ends to fully expose the underlying spinal
cord. The spinal cord was completely transected at T8 with
microscissors, as were the adjacent underlying dorsal and ventral
roots.
Chitosan channels containing NSPCs in the fibrin scaffold were
then implanted by placing the transected stumps into the channel
openings. Treatment groups are described in Table 1. Channels
were positioned symmetrically such that the caudal and rostral
stumps were inserted equidistant inside the channel, approximate-
ly 2 mm, so that the gap between the stumps was approximately
4 mm. The spinal cord stumps were inserted sufficiently far into
the channel so that the stumps were in apposition to the fibrin
scaffolds within the channels. A 4 mm63 mm sheet of Gore-Tex
Preclude MVP membrane (Gore-Tex, Flagstaff, AZ) was placed at
each end covering the channel-spinal cord interface. 30 ml of fibrin
glue (Beriplast P, provided generously from CSL Behring) was
then applied to secure the stumps to the implant. The overlying
muscle and skin were closed with 3-0 Vicryl sutures (Ethicon) and
metal clips, respectively.
Rats were given buprenorphrine post-surgery, and every 8–12 h
for the next 48 h. Immunosuppression with cyclosporine-A
(15 mg/kg) was administered daily via subcutaneous injection.
Functional recovery was assessed using the Basso, Beattie, and
Bresnahan (BBB) open field locomotor scale [32] once a week. The
scores for the left and right hindlimb were averaged for each
animal at each timepoint.
Tissue Preparation
At either 2 or 6 weeks post-implantation, animals were
sacrificed via transcardial perfusion with 4% paraformaldehyde
in 0.1 M PBS, pH 7.4. Spinal cords were removed and
cryoprotected in 30% sucrose for a minimum of 24 h. The length
of cord encompassing the implant site, as well as 2–3 mm on either
side, was removed for sectioning. Tissue was cut as 20 mm
cryosections onto Superfrost Plus slides (Fisher Scientific, Mark-
ham, ON) in 1:10 series and stored at 280uC. For the 6 week
animals, one sample from each treatment group was cut
parasaggitally. All other 6 week samples, and all 2 week samples,
were cut as cross-sections.
Tissue analysis
To quantify cell survival, every tenth section was stained with
DAPI (Vectashield) and imaged under fluorescence to detect the
GFP-positive transplanted cells. Cell counts were calculated by
manually counting GFP-positive cells associated with DAPI-
stained nuclei across the sample and extrapolating by a factor of
ten. False positive signals associated with autoflourescence were
eliminated by also imaging under the Cy3 filter.
For immunohistochemical analysis of tissue sections, slides
washed with PBS then blocked in 2% goat serum and 0.3% Triton
X-100 for 1 h. Primary antibodies were incubated in block or PBS
overnight at 4uC. After three consecutive 10 min PBS washes,
slides were incubated with secondary antibody in PBS for 1 h.
Following another 3 washes, sections were coverslipped with
Vectashield anti-fade mount containing DAPI. Some sections were
double-labelled. In these cases the second primary-secondary
antibody pairings was stained following the first pairing.
Primary antibodies used were mouse and rabbit anti-betaIII
tubulin (1:1000, Covance), mouse anti-bIII tubulin (1:1000,
Covance) for neurons, mouse anti-GFAP (1:200, Millipore) for
astrocytes, mouse anti-CC1 (1:1000, Calbiochem) for oligoden-
drocytes, mouse anti-nestin (1:100, BD Biosciences) for neural
precursors, mouse anti-3CB2 (1:50, Hybridoma Bank) for radial
glia, mouse anti-Reca1 (1:100, Serotec) for endothelial cells, mouse
anti-prolyl-4-hydroxylase (1:100, Millipore) for fibroblasts, mouse
anti-GFP (1:400, Invitrogen) for green fluorescent protein, and
mouse anti-Ki67 (1:100, Novocastra Laboratories Ltd) for
proliferating cells. Secondary antibodies included goat anti-mouse
Alexa 568 (Invitrogen), goat anti-rabbit Alexa 568 (Invitrogen),
goat anti-mouse Alexa 647 (Invitrogen), and goat anti-mouse Cy5
(Jackson Immuoresearch) all at 1:500. Images for differentiation
analysis were taken on a Zeiss Observer Z1 confocal microscope
using Volocity 4.3.2 software. A minimum of ten random fields
containing the GFP-positive transplanted NSPCs were photo-
graphed over multiple tissue sections for each animal per stain.
Phenotypic analysis of transplanted NSPCs was calculated based
on identification of GFP-positive cells associated with a DAPI-
stained nucleus and the immunohistological marker of interest.
Statistics
Comparisons involving one independent factor (eg. treatment)
or two independent factors (eg. treatment and time) were analyzed
using one-way and two-way ANOVA, respectively, followed by
Bonferroni post-hoc testing. P-values less than 0.05 were used as
the criteria for statistical significance. Statistical analysis was
performed using GraphPad Prism software. All values are
represented as mean 6 standard deviation.
Results
Dibutyryl Cyclic-AMP Promotes Neuronal Differentiation
of NSPCs
NSPCs were cultured on chitosan films and exposed to varying
concentrations of dbcAMP for 7 d, then stained with the neuronal
marker betaIII tubulin to quantify its effect on directed neuronal
differentiation (Figure 1A). In the absence of dbcAMP, NSPCs
produced very few neurons (1.461.2%). At increasingly higher
dbcAMP concentrations, the percentage of betaIII tubulin-positive
cells also increased, reaching as high as 94.560.5% with 4 mM
dbcAMP. 1 mM dbcAMP, which produced 84.864.8% neurons, was
selected as the target concentration for subsequent studies because it
resulted in greater numbers of total cells compared to 4 mM.
A more complete differentiation profile was performed on
NSPCs treated with dbcAMP (Figure 1B–J). NSPCs were cultured
for 7 d with either no dbcAMP, 1 mM dbcAMP for the first day
only, or 1 mM dbcAMP for all 7 days. All groups contained 1%
FBS in the media. Only with prolonged exposure to dbcAMP was
extensive neuronal differentiation seen. This was in contrast to 1 d
dbcAMP exposure which resulted in only 7.763.6% neurons. The
increase in neurons with extended dbcAMP treatment was
accompanied by a decrease in the percentages of RIP-positive
oligodendrocytes (7.063.4% vs. 21.1611.4% in FBS alone) and
nestin-positive progenitor cells (12.764.5% vs. 33.969.6% in FBS
alone). Very few GFAP-positive astrocytes were produced, with or
without dbcAMP, as is typical for our population of brain-derived
rat NSPCs [12,14], particularly on when cultured chitosan
substrate [31]. One day treatment with dbcAMP had no effect
on differentiation compared to FBS controls.
Cell density was notably lower in dbcAMP-treated wells after
7 d, suggesting either cytotoxic or anti-proliferative effects of the
drug. To investigate this, NSPCs were characterized at 1, 3, and
7 d for total cell number, as well as for markers of proliferation
and differentiation (Figure 1K,L). Prolonged exposure to dbcAMP
in culture had no effect on total cell numbers after 3 d, but there
was a clear anti-proliferative effect by 7 d where dbcAMP largely
promoted post-mitotic neuron formation. Ki67 staining for
proliferating cells was 4-fold lower for dbcAMP-treated cells
Effects of Dibutyryl Cyclic-AMP on NSPC Fate
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to have a direct effect on promoting neurons vs. being selectively
cytotoxic to glial cells because oligodendrocyte and astrocyte
populations did not decrease over time (Figure 1M).
PLGA Microspheres for dbcAMP Release
Based on the in vitro data where the greatest neuronal
differentiation was observed in the presence of constant dbcAMP
for 7 d, dbcAMP was encapsulated in PLGA microspheres and the
Figure 1. NSPCs respond to dbcAMP in vitro.A ) Dose response curve of dbcAMP on neuronal differentiation of NSPCs after 7 days in culture.
B) Differentiation profile of NSPCs after 7 days. NSPCs were treated with media containing 1 mM dbcAMP for 0, 1 or 7 days. Only sustained exposure
to dbcAMP resulted in increased number of BetaIII-positive neurons. C–J) Representative images of NSPCs after 7 days in culture for markers of
progenitors cells (nestin), neurons (BetaIII), oligodendrocytes (RIP), and astrocytes (GFAP). Scale bar represents 100 mm. K) Cell numbers at 1, 3, and 7
days in culture with or without 1 mM dbcAMP. L) Ki67 staining for proliferating cells after 3 days. M) Cell differentiation over time with or without
1 mM dbcAMP treatment. Data represented as mean 6 standard (n=3 to 9). Statistical differences denoted by *, p,0.05.
doi:10.1371/journal.pone.0021744.g001
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efficiency of dbcAMP was 80% and the loading was 19 wt%.
Release curves of dbcAMP from PLGA microspheres, both free-
floating in buffer and embedded within chitosan channels, are
shown in Figure 2A. Drug release from native microspheres was
linear over 11 days. Once incorporated into channels, the release
of dbcAMP occurred over approximately 5 days, after which the
drug contents are depleted. This discrepancy in release profiles is
largely due to drug losses during the process of embedding
microspheres into the channel. This was confirmed by mass
balance which showed less drug content in dbcAMP microsphere-
loaded channels than expected based on microsphere quantity.
NSPC Differentiation in Microsphere-Loaded Channels
DbcAMP-loaded microspheres were incorporated into chitosan
channels and tested for their efficacy in differentiating NSPCs in
three-dimensional constructs, as depicted in Figure 2B. NSPCs
were seeded into fibrin scaffolds and cultured within microsphere-
loaded channels containing either no drug or dbcAMP. After
seven days, NSPCs in three-dimensional fibrin scaffolds were well
distributed and viable as assessed by calceinAM (live)/ethidium
homodimer (dead) staining (Figure 2C).
NPSCs remained responsive to dbcAMP in 3D fibrin scaffolds
(Figure 2D–H). NSPC cultured in media containing 1 mM
dbcAMP for 7 days resulted in 5465% betaIII-positive neurons,
while NSPCs cultured with dbcAMP-releasing microspheres
resulted in approximately 3764% neurons. Both groups had
significantly greater percentages of neurons than NSPCs cultured
without dbcAMP, or dbcAMP for only the first 24 h, which
resulted in only 763% and 1164% neuronal differentiation,
respectively. Quantitative RT-PCR measurement of betaIII-
tubulin mRNA showed a similar trend of expression between
treatment groups, further supporting the immunostaining data
(Figure 2I,J).
In vivo NSPC Transplantation
NSPCs were seeded in the fibrin scaffold within channels and
incubated 1 or 4 days in vitro (div) prior to transplantation (see
Table 1). The 1 div samples included NSPCs seeded in channels
containing blank or dbcAMP-releasing microspheres. These
groups were transplanted after only one day incubation to ensure
that the majority of dbcAMP released from microspheres occurs in
vivo. The 4 div groups included both NSPCs pre-differentiated
(40% betaIII-tubulin-positive neurons) in 1 mM dbcAMP media
Figure 2. Microsphere-loaded channels effectively release dbcAMP in vitro.A ) Cumulative release profiles of dbcAMP from free-floating
microspheres and microsphere-loaded channels. The process of embedding microspheres into channel walls is likely responsible for early
degradation of PLGA and faster drug release from channels. B) Schematic of the entubulation strategy. NSPCs are seeded on fibrin scaffold within a
chitosan channel. Drug-loaded PLGA microspheres release the differentiation factor dibutyryl cyclic-AMP in a local and sustained manner, influencing
NSPCs to preferentially differentiate into neurons. C) Viability of NSPCs in a three-dimensional fibrin scaffold. Simultaneous staining of CalceinAM
(green) and Ethidium homodimer (red) for live and dead cells respectively show good cell viability of NSPCs in fibrin scaffolds at 1 week. Scale bar
represents 100 mm. D–G) Immunostaining of NSPCs for DAPI-nuclear stain and betaIII-tubulin with various dbcAMP treatments. Scale bar represents
100 mm. H) Quantification of betaIII-tubulin immunostained NSPCs with various dbcAMP treatments. I,J) Quantitative RT-PCR data for (I) betaIII
tubulin and (J) nestin mRNA expression with various dbcAMP treatments, normalized to housekeeping gene HPRT. Data represented as mean 6
standard (n=3 to 6). Statistical differences denoted by *, p,0.05.
doi:10.1371/journal.pone.0021744.g002
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numbers at the time of transplantation are listed in Table 1. The
decrease in cell numbers for the 4 div groups was attributed to
incubation in serum-free media.
The channels were implanted following spinal cord transection,
with the spinal cord ends abutting the ends of the fibrin scaffold
(Figure 3A). After two and six weeks, animals were sacrificed.
Robust tissue bridges across the injury site formed as early as two
weeks (Figure 3B). As shown in Figures 3C and D, GFP-positive
transplanted NSPCs were found throughout the bridge tissue. Cell
transplant survival was assessed by GFP-positive cell counts
(Figure 3E). At 2 weeks, NSPCs pre-treated with free dbcAMP
resulted in significantly higher cell survival, approximately 80%,
compared to both untreated NSPCs (1 div or 4 div) and NSPCs
implanted in chitosan channels with dbcAMP microspheres. Cell
survival percentages did not differ between two and six weeks for
any treatment group. Staining for the proliferative marker Ki67
was very low for NSPCs at two weeks (data not shown). There was
no definite migration of NSPCs into the spinal cord stumps.
Six week animals were also monitored weekly for hindlimb
function using the BBB motor function scale. A small but
statistically significant increase in hindlimb movement at 6 weeks
was observed in animals receiving NSPCs pre-treated with
dbcAMP for 4 div compared to untreated NSPCs (Figure 3F).
Figure 3. Channel implantation after spinal cord transection facilitates tissue bridging, NSPC survival, and behavioural
improvement over time. A) Photograph of the surgical implantation of fibrin-filled chitosan channels. B) Tissue bridges obtained from animals
2 weeks after implantation. C,D) Longitudinal section of tissue bridge demonstrating NSPC survival after 6 weeks in an animal receiving dbcAMP pre-
treatment (dbcAMP, 4div). Boxed area in (C) is magnified in (D). E) NSPC survival after 2 and 6 weeks for various treatment groups. F) Assessment of
functional recovery using the BBB locomotor scale. After 6 weeks, rats receiving transplants of dbcAMP-pre-treated NSPCs show a statistically
significant increase in hindlimb function relative to untreated animals (*, p,0.05). Mean 6 standard deviation shown for n=4 to 6.
doi:10.1371/journal.pone.0021744.g003
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results are summarized in Figure 4. All four groups expressed low
levels of nestin showing that few NSPCs remained as uncommitted
progenitors. BetaIII-tubulin staining show about 15% neuronal
differentiation for NSPCs not exposed to dbcAMP (both 1 div and
4 div). NSPCs pre-treated with dbcAMP resulted in 37.064.1%
neurons after two weeks, similar to time-of-transplant values.
Treatment with dbcAMP microspheres resulted in an intermediate
percentage of neurons, 26.7613.9%. CC1-staining for oligoden-
drocytes was highest for untreated NSPCs (27.9611.7% and
33.8616.5% for 1 div and 4 div, respectively) and lowest for
dbcAMP pre-treated NSPCs (3.963.8%). Similarly, GFAP-
staining for astrocytes was also highest for untreated NSPCs
(30.3612.8% and 29.3610.3% for 1 div and 4 div, respectively)
and lowest for dbcAMP pre-treated NSPCs (3.563.6%).
DbcAMP-microsphere treated NSPCs resulted in intermediate
percentages of oligodendrocytes and astrocytes (10.9613.2% and
17.7611.6%, respectively) which were not significantly different
from either untreated or pre-treated groups. Staining for mature
neuronal markers MAP2 and NeuN were negative across all
groups. Transplanted NSPCs were also negative for the radial glia
marker 3CB2.
At six weeks, despite similar cell survival numbers, the majority
of transplanted NSPCs had lost expression of the typical CNS
phenotypic markers used above, independent of treatment.
Staining with an antibody against the GFP-antigen resulted in
positive staining (data not shown), indicating that tissue prepara-
tion was not an issue. Large populations of unclassified NSPCs
have been reported previously [5,9]. It is interesting to note that,
particularly in the dbcAMP-pre-treated animals, the surviving
NSPCs seemed to form continuous networks across the bridge,
with highly ordered longitudinal orientation (Figure 3C,D). Cell
morphology suggests a more mature phenotype with elongated cell
bodies and processes. A small subset of the dbcAMP pre-treated
cells were betaIII-tubulin positive at six weeks (Figure 4N),
although staining with mature neuronal markers MAP2 and NeuN
were largely negative.
Axonal regeneration across the bridge was also investigated.
Interestingly, all treatment groups at six weeks resulted in
numerous betaIII tubulin-positive axons penetrating the bridge
from the rostral stump but stopping as they approached the caudal
stump, as illustrated in Figure 5A. These axons were not GFP-
positive, indicating that they originated from the host. Double
labelling of betaIII-tubulin with synaptophysin, a neural synaptic
marker, shows that there is some association between the
endogenous axons and the transplanted GFP-positive cells
(Figure 5B). Also present in the bridge are RECA1 positive
endothelial cells, which form discrete blood vessels as early as two-
weeks (Figure 5C). No apparent association was found between
blood vessel formation and treatment, or blood vessel vicinity to
surviving NSPCs. Apart from the GFP-positive transplanted
NSPCs, the tissue bridge was composed mainly of prolyl-4-
hydroxylase-positive, collagen-producing fibroblasts at 6 weeks
(Figure 5D). GFP-positive transplanted NSPCs were negative for
the fibroblast marker.
Discussion
In this study, we aimed to understand the role of prolonged
dbcAMP exposure on neuronal differentiation and the impact of
pre-differentiated vs. in situ differentiated neurons on their survival
and integration in vivo. By using the fully transected spinal cord
injury model, we could clearly follow the effect of differentiated
stem cells on tissue regeneration and locomotor functional
recovery. The entubulation strategy, with which we have
significant experience [9,10,33,34], is most suitable for these full-
transection studies. The incorporation of dbcAMP-releasing
microspheres in the tube walls allowed us to investigate the timing
of differentiation on survival.
Interestingly, enhanced neuronal differentiation was observed
with only prolonged, 7 d dbcAMP exposure and thus necessitated
the inclusion of a prolonged release strategy in the chitosan tubular
construct design. PLGA microspheres were fabricated and tailored
for short-term release of dbcAMP and embedded into chitosan
channels. In order to facilitate 7 d in vitro cultures, NSPCs were
encapsulated in fibrin scaffolds that were incorporated into the
channels. While previous studies have had NSPCs seeded along
the interior walls of the channels [9,10], this was impractical for
prolonged in vitro culture where cell proliferation resulted in cells
dislodging from the channel surface. Fibrin scaffolds not only
provided better entrapment of NSPCs, but also resulted in
improved consistency in cell number and distribution. Fibrin
scaffolds form quickly from fibrinogen and thrombin, and have
been shown to be safe for cells in culture [35] and in vivo [36]. After
spinal cord injury, fibrin scaffolds have been shown to attenuate
glial scar formation [37]. Moreover, we have previously shown
that guidance channels filled with fibrin matrix promote axonal
regeneration and functional recovery after spinal cord transection
[34]. The cell differentiation data of NSPCs cultured in fibrin-
filled, microsphere-loaded channels for 7 days in vitro confirmed
that NSPCs are still dbcAMP-responsive in 3D fibrin scaffolds.
More importantly, the NSPCs preferentially differentiated into
neurons when cultured in channels where microspheres provided
the only source of dbcAMP, validating microsphere-loaded
channels as an effective drug delivery system in vitro. Although
the neuronal differentiation percentage with dbcAMP on fibrin
scaffolds was not as high as that on 2D chitosan films (,50% vs.
,80%), the effect was still a marked increase over non-dbcAMP
treated cells (7%). It is possible that a higher target dose of
dbcAMP may compensate for this decrease in neuronal differen-
tiation, but this was not investigated. Cell fate determination is a
complex process that not only depends on presence of soluble
factors and time, but is also influenced by surface chemistry/
adhesion [38] and mechanical properties [31,39], so it was
important to confirm that NSPCs would respond to dbcAMP in
the three-dimensional fibrin matrix.
To better understand the benefit of pre-differentiated neurons
vs. in situ (via dbcAMP-releasing microspheres), neuronal differ-
entiation and survival were studied in vivo, in a fully-transected SCI
rat model. Untreated NSPCs served as controls. Unexpectedly,
NSPCs pre-differentiated with dbcAMP prior to transplantation
resulted in a striking increase in cell survival of 80% whereas both
untreated and dbcAMP-microsphere-treated NSPCs had survival
rates of approximately 15%. There were no significant changes in
survival of transplanted NSPCs between two and six weeks within
a given treatment. Paired with low level of staining with Ki67
proliferative marker, this suggests that the NSPC population had
stabilized between these two time points. The enhanced survival
effect associated with the dbcAMP 4 div group is attributed
directly to pre-treatment with dbcAMP, as this was not observed
with in situ dbcAMP delivery (dbcAMP-MS 1 div) nor in matching
untreated controls (untreated 4 div) which would account for the
extended in vitro incubation time including scaffold integrity, cell
distribution, adhesion, or other factors.
Survival effects have been previously associated with dbcAMP
pre-treatment, which can provide neuroprotection against excito-
toxicity [40]. Rolipram, a phophodiesterase-IV inhibitor that
works primarily by increasing intracellular cAMP [41], has been
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Moreover, downstream pathways of cyclic-AMP are important for
the survival of newly generated neurons during development [44].
Recently, Nout et al. used combined rolipram and dbcAMP drug
treatment with glial restricted precursor cell transplants and
observed reduced transplant survival with dbcAMP treatment
[45]. However, the concentration of dbcAMP used in that study
was 50 mM. Concentrations of 1 mM, as used in this study, are
well-tolerated in the spinal cord whereas high doses can be
damaging [46]. Rolipram-based elevation of cAMP has been
shown to increase survival of transplanted olfactory ensheathing
cells [43], and in combination with Schwann cell grafts, was
implicated in axonal sparing [47]. The present study shows no
effect on transplant survival with in situ dbcAMP delivery
compared to no dbcAMP treatment, suggesting that enhanced
transplant survival resulted from either a priming or pre-
differentiation effect.
Pre-differentiation or pre-commitment of stem cells down a
specific lineage may account for greater survival. Tarasenko et al.
reported marginally higher survival when neuronally committed
progenitor cells versus undifferentiated cells were transplanted in
the injured CNS [48]. Olstorn et al. transplanted two preparations
of human NSPCs in ischemic brain, demonstrating that both
undifferentiated and neuronally-committed NSPCs were able to
migrate towards the lesion site [49]. However, no differences in
survival between the two preparations were reported. Davies et al.
pre-treated glial restricted precursors with bone morphogenic
protein-4 (BMP4) to derive immature astrocytes and explored the
differences between the two populations after transplantation into
lesioned rat spinal cord [50]. They found that pre-differentiated
astrocytes better integrated with host regenerating tissue by
supporting axonal regeneration and reducing astrogliosis. Inter-
estingly, this group found that pre-differentiated astrocytes from
ciliary neurotrophic factor (CNTF)-treated precursors had a
detrimental effect [51] versus the beneficial effect observed with
BMP4, indicating that subtle differences in the pre-differentiated
progeny can significantly alter in vivo behaviour. Committed
oligodendrocytes also performed better than undifferentiated
NSPCs, showing better ability to remyelinate denuded spinal
cord axons [52]. However, pre-differentiation of NSPCs to
neurons is not always beneficial. For example, neuronal pre-
differentiation resulted in poorer engraftment and survival than
that achieved with undifferentiated NSPCs in hippocamppal
transplant studies for Parkinson’s disease [53,54]. The extent of
differentiation or perhaps maturation down a specific lineage may
be of great importance. The 4 div with dbcAMP exposure ensured
differentiation down the neuronal lineage; however, the differen-
tiated progeny are unlikely fully mature, thereby promoting their
Figure 5. The regenerated bridge tissue contains host axons, blood vessels, and fibroblasts. A) Representative image of endogenous
axonal regeneration into the tissue bridge based on betaIII tubulin staining. B) Evidence of association between betaIII-positive endogenous axons
with surviving GFP-positive NSPCs at six weeks. Synaptophysin staining is observed at the interface (inset). C) RECA1 staining for endothelial cells
show blood vessel formation throughout the tissue bridge at 2 weeks. D) Prolyl-4-hydroxylase (rPH) staining of bridge tissue indicates that the
majority of cells are collagen producing fibroblasts.
doi:10.1371/journal.pone.0021744.g005
Figure 4. Differentiation profiles of NSPCs are impacted by dbcAMP treatment. A–L) Representative images of tissue samples
demonstrating NSPC differentiation profile of (A–C) nestin-positive progenitor cells, (D–F) BetaIII-positive neurons, (G–H) CC1-positive
oligodendrocytes, and (J–L) GFAP-positive astrocytes. Scale bar represents 50 mm. M) Quantification of NSPC differentiation profile for the various
treatment groups. Mean 6 standard deviation are plotted, n=3 to 5; significant differences noted with an asterisks, p,0.05. N) Deconvoluted
confocal image of betaIII-positive NSPC-derived neurons (arrows) 6 weeks post-transplantation. Scale bar represents 50 mm.
doi:10.1371/journal.pone.0021744.g004
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not mature, phenotype for enhanced survival in vivo may allow
greater integration.
Pre-treatment of dbcAMP resulted in the highest number of
betaIII-tubulin positive neurons after two weeks in vivo, while the
lowest percentage of neurons was associated with cells not exposed
to dbcAMP, whether cultured for 1 or 4 div prior to transplant.
The increased percentage of neurons in dbcAMP pre-treated
NSPCs came at the expense of oligodendrocyte and astrocyte
differentiation, which were both higher in untreated NSPCs.
Although not statistically significant, in situ delivery of dbcAMP via
microspheres consistently resulted in differentiation values that
were between dbcAMP pre-treated and untreated groups. This
suggests that dbcAMP-microspheres were likely able to influence
NSPC fate in vivo, but that certain parameters of the delivery might
be lacking, for example drug concentration or length of
administration. Indeed, release parameters of PLGA microspheres
can differ between an in vitro and in vivo environment. Using radio-
labelling, de Boer et al. showed linear but more rapid release when
comparing in vitro and in vivo release profiles of nerve growth factor
from PLGA microspheres [55]. Technical restraints limited that
study to a subcutaneous model, and indeed even more rapid
degradation and release would be expected in injured tissue where
acidic pH would cause accelerated degradation of the PLGA.
The tissue bridge had a high density of cells, the majority of
which were collagen-producing fibroblasts, likely of meningeal
origin from the disrupted pia, arachnoid, and dura. Angiogenesis
was apparent as early as two weeks throughout the bridge, as
evidenced by RECA1-postive staining of blood vessels. Notably,
endogenous axonal regeneration into the bridge was observed in
all treatment groups, and all showed initiation from the rostral
stump of the spinal cord. However, the axons encountered a
barrier at the caudal end of the bridge, from the glial scar which
prevented penetration into the caudal stump of the spinal cord.
Complete spinal cord transection is the most severe injury
model that results in zero hindlimb movement immediately after
injury. Typically rats will spontaneously recover only a very
limited range of motion in the lower limbs over time. In this study,
we showed that animals receiving dbcAMP pre-treated NSPCs
showed a small but statistically significant (p,0.05) improvement
in hindlimb function resulting in some movement of hindlimb
joints. A strong histological basis for this improvement is not
apparent, as endogenous axonal regeneration across the tissue
bridge did not appear to be qualitatively different among
treatment groups. It is possible that some of the surviving NSPCs
which spanned the entire length of the bridges, contributed to the
observed enhanced functional recovery. Indeed, these transplanted
cells appear to associated closely with each other to form a
continuous network (Figure 3C,D). Directed differentiation of
NSPCs into neurons has been reported by others to improve
functional outcome after experimental SCI [56,57]. We did
observe synapse formation between host axons and surviving
NSPCs, which may underlie this minimal recovery if the axons
from these surviving transplanted cells reached any of the motor
neurons in the distal spinal cord. However, the apparent loss of
neuronal phenotype of our transplanted NSPCs at six weeks
suggests that a neuronal relay in the traditional sense may not be
the mechanism responsible for the observed enhanced function.
Additional locomotor recovery would have likely continued in all
groups at longer timepoints as BBB scores had not yet plateaued
after six weeks. Thus, it is possible that dbcAMP pre-treatment
does not enhance long-term functional outcome, but only
accelerates the rate of recovery.
Cell transplant strategies offer great potential for replacing lost
and damaged tissue. Drug treatments and biomaterial scaffolds
further improve the efficacy of transplant cell survival and
differentiation, as well as promote endogenous tissue regeneration.
Our entubulation strategy combines these three aspects of
treatment and has shown to be efficacious in promoting NSPC
survival and host axonal regeneration.
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